Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 14, 2021

(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence. federal law. Karl Kottmeier” President.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

The Cannigma

DECEMBER 12, 2022

Many psychedelics are also referred to as entheogens, which are substances that expand consciousness for religious or spiritual purposes. This decrease in DMN activity from psychedelics is sometimes referred to as “ego death,” and can be therapeutic to reset unhealthy thought patterns, almost like a brain reboot. Are psychedelics safe?

History 119

History Microdosing Research and Development Clinical Trials 119

The Cannigma

JULY 1, 2022

Preclinical studies involve exposing cells and animals to treatments to see if there are indications that the treatment could be worth evaluating in humans. Clinical studies are performed in people and can be controlled in various ways to understand how people respond to a treatment.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Based on my clinical experience, it is rare for people to experience CBD-drug interactions at doses below 100mg daily. .

CBD 98

CBD THC Conditions Medicine 98

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

SEPTEMBER 24, 2019

We’re presuming both names “Epidyolex” & “Epidiolex” refer to exactly the same product and the former is the US product name and the latter the European brand name. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Based on my clinical experience, it is rare for people to experience CBD-drug interactions at doses below 100mg daily. [2].

CBD 52

CBD THC Conditions Medicine 52

Veriheal

JUNE 29, 2022

Psilocybin , a psychedelic compound found in a variety of mushrooms, has long been used as a tool to mitigate depression despite the limited amount of research on its efficacy and safety. Exploring Psilocybin and Treatment-Resistant Depression. Future Trials With COMP360 Psilocybin. Dr. David J.

Clinical Trials 103

Clinical Trials Blood Pressure Treatment Therapy 103

Cannabis Law Report

JUNE 11, 2019

Given the controversy over the efficacy and safety of cannabis for therapeutic purposes, a key question in these cases, is whether cannabis meets the requirement of medical justification. Compensation is not payable for treatments that “simply improve the plaintiff’s enjoyment of life” 32. Siegrist with approval.

Chronic Pain 45

Chronic Pain Cannabis History Treatment 45

Project CBD

FEBRUARY 28, 2023

Under section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act — in what some refer to as the “drug preclusion clause” 4 — any substance that is an active ingredient in an approved drug product, or that is being publicly investigated as such, is excluded from the definition of a legal dietary supplement ingredient. 2021.06.005.

CBD 144

CBD Seed-To-Sale Food Access 144

Veriheal

SEPTEMBER 21, 2023

However, it is also commonly referred to as the Colorado River toad. The toad’s secretion has been referred to as “the most potent psychedelic toad venom on Earth.” The psychedelic has huge potential to significantly reduce the cost of treatment. They can be found in Arizona, Colorado, and New Mexico.

Clinical Trials 113

Clinical Trials Therapy Conditions Pets 113

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Advance to FDA IND-enabling studies to support human clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Alchimia

FEBRUARY 1, 2022

Neuroprotective : could contribute to the treatment of neurodegenerative diseases such as multiple sclerosis. To date, there are several studies that have tried to verify the safety and toxicology of CBD when it is administered to treat certain diseases. What are the side effects of CBD? Drowsiness. Reduced appetite/weight changes.

CBD 52

CBD Epilepsy Research and Development Cannabinoids 52

Peninsula Alternative Health

MAY 15, 2019

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response. tetrahydrocannabinol (THC).

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

MAY 6, 2021

Other than serving as a lighter version of delta-9-THC, delta-8 has also been researched as a potential treatment for a number of medical conditions and symptoms such as vomiting and nausea, glaucoma, pain, and inflammation. When it comes to safety, the two main factors to consider are production (standards and regulation) and research.

THC 145

THC Cannabinoids Concentrates Hemp 145

Peninsula Alternative Health

MAY 15, 2019

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response. tetrahydrocannabinol (THC).

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement. Wakshlag, DVM, Ph.D.,

Safety 45

Safety CBD Clinical Trials Oil 45